skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine (Code C48394)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine

Definition: A peptide vaccine comprised of synthetic HLA-A2- and HLA-A3-binding peptides, derived from amino acid sequences of fibroblast growth factor-5 (FGF-5), combined with the adjuvant Montanide ISA-51 with potential antineoplastic activity. HLA-A2, A3-restricted FGF-5 peptides contain motifs recognized by the MHC class I molecules HLA-A2 and HLA-A3 and may stimulate a cytotoxic T-cell response against tumor cells that overexpress FGF-5. Montanide ISA-51, a stabilized water-in-oil emulsion adjuvant containing mineral oil with mannide oleate added as a surfactant, non-specifically stimulates cell-mediated immune responses to antigens.

Label: HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine

NCI Thesaurus Code: C48394 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1541599  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
HLA-A2, A3-Restricted FGF-5 Peptides/Montanide ISA-51 Vaccine

External Source Codes: 
PDQ Closed Trial Search ID 387966
PDQ Open Trial Search ID 387966 (check for NCI PDQ open clinical trial info)
UMLS CUI C1541599

Other Properties:
     Name Value (qualifiers indented underneath)
code C48394
Legacy_Concept_Name HLA-A2_A3-Restricted_FGF-5_Peptides_Montanide_ISA-51_Vaccine
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom